NBTXR3

Other

Phase 3underway

Evidence outlook · registrational

Head and Neck Squamous Cell Carcinoma: registrational readout pending

No completed mid-stage readout is on record. Registrational readout expected around 2028-06-30.

Also in development:Non-Small Cell Lung Cancer · Phase 2

How the evidence outlook works ↗

All registered studies

Every ClinicalTrials.gov study of this drug's own program. Studies backing a featured trial above are marked Featured; the rest aren't individually graded. Filter by which indication a study was run for, then browse by phase.

Phase 3 (1)
Other / comorbidity
Phase 2/3 (1)
Other / comorbidity
NCT02379845 · Nanobiotix
2015-03-03 – 2020-09-20 · Adult Soft Tissue Sarcoma
What this study did
Phase 2 (3)
Head and Neck Squamous Cell Carcinoma
NCT04862455 · M.D. Anderson Cancer Center
2021-04-07 – 2026-01-21 · Metastatic Head and Neck Squamous Cell Carcinoma, Recurrent Head and Neck Squamous Cell Carcinoma
What this study did
NCT04834349 · M.D. Anderson Cancer Center
2021-03-09 – 2022-11-21 · Recurrent Head and Neck Squamous Cell Carcinoma, Unresectable Head and Neck Squamous Cell Carcinoma
What this study did
Non-Small Cell Lung Cancer
NCT06667908 · Johnson & Johnson Enterprise Innovation Inc.
2024-12-06 – 2028-12-31 · Carcinoma, Non-Small-Cell Lung
What this study did
Phase 1/2 (6)
Head and Neck Squamous Cell Carcinoma
NCT02901483 · PharmaEngine
2016-10-11 – 2020-08-17 · Head and Neck Squamous Cell Carcinoma
What this study did
Non-Small Cell Lung Cancer
Other / comorbidity
NCT05039632 · M.D. Anderson Cancer Center
2023-05-08 – 2028-02-01 · Advanced Malignant Solid Neoplasm, Metastatic Malignant Neoplasm in the Liver, Metastatic Malignant Neoplasm in the Lung, Metastatic Malignant Solid Neoplasm
What this study did
NCT02465593 · PharmaEngine
2015-06 – 2021-07-28 · Rectal Cancer
What this study did
NCT02721056 · Nanobiotix
2016-01-28 – 2020-05-06 · Liver Cancer
What this study did
NCT02805894 · Nanobiotix
2017-11-15 – 2020-03-19 · Prostate Cancer
What this study did
Phase 1 (6)
Head and Neck Squamous Cell Carcinoma
NCT07219212 · Johnson & Johnson Enterprise Innovation Inc.
2026-01-26 – 2028-07-14 · Squamous Cell Carcinoma of Head and Neck
What this study did
Non-Small Cell Lung Cancer
NCT04505267 · M.D. Anderson Cancer Center
2021-02-10 – 2028-03-31 · Recurrent Lung Non-Small Cell Carcinoma, Stage I Lung Cancer AJCC v8, Stage IA1 Lung Cancer AJCC v8, Stage IA2 Lung Cancer AJCC v8, Stage IA3 Lung Cancer AJCC v8, Stage IB Lung Cancer AJCC v8, Stage II Lung Cancer AJCC v8, Stage IIA Lung Cancer AJCC v8, Stage IIB Lung Cancer AJCC v8, Stage III Lung Cancer AJCC v8, Stage IIIA Lung Cancer AJCC v8, Stage IIIB Lung Cancer AJCC v8, Stage IIIC Lung Cancer AJCC v8, Unresectable Lung Non-Small Cell Carcinoma
What this study did
Other / comorbidity
NCT04615013 · M.D. Anderson Cancer Center
2020-11-23 – 2027-10-31 · Cervical Esophagus Adenocarcinoma, Clinical Stage II Esophageal Adenocarcinoma AJCC v8, Clinical Stage IIA Esophageal Adenocarcinoma AJCC v8, Clinical Stage IIB Esophageal Adenocarcinoma AJCC v8, Clinical Stage III Esophageal Adenocarcinoma AJCC v8, Gastroesophageal Junction Adenocarcinoma, Pathologic Stage II Esophageal Adenocarcinoma AJCC v8, Pathologic Stage IIA Esophageal Adenocarcinoma AJCC v8, Pathologic Stage IIB Esophageal Adenocarcinoma AJCC v8, Pathologic Stage III Esophageal Adenocarcinoma AJCC v8, Pathologic Stage IIIA Esophageal Adenocarcinoma AJCC v8, Pathologic Stage IIIB Esophageal Adenocarcinoma AJCC v8, Thoracic Esophagus Adenocarcinoma
What this study did
NCT04484909 · M.D. Anderson Cancer Center
2020-07-01 – 2026-12-31 · Borderline Resectable Pancreatic Adenocarcinoma, Locally Advanced Pancreatic Ductal Adenocarcinoma, Resectable Pancreatic Ductal Adenocarcinoma, Stage III Pancreatic Cancer AJCC v8
What this study did
NCT01433068 · Nanobiotix
2011-10 – 2015-02 · Adult Soft Tissue Sarcoma
What this study did
Early phase / not applicable (1)
Head and Neck Squamous Cell Carcinoma
NCT01946867 · Nanobiotix
2014-01-03 – 2023-02 · Head and Neck Cancer
What this study did

Competitive landscape

This drug's own stage for Head and Neck Squamous Cell Carcinoma: Phase 3. Competitors below are sorted furthest-along first.

DrugStageModalityMechanismEvidence signalReported efficacygraded featured trials
NBTXR3: this drugPhase 3NanoparticleHafnium-oxide nanoparticle radioenhancernot yet gradedNo reviewed efficacy summary in this indication
CetuximabApprovedMonoclonal antibodyEGFRPartial signal
NCT00122460: Overall Survival Time (OS) (time from randomization to death or last day known to be alive, reported between day of first patient randomised, 21 Dec 2004, until cut-off date 12 Mar 2007): Cetuximab Plus Chemotherapy 10.1 months (95% CI 8.6 to 11.2) | Chemotherapy Alone 7.4 months (95% CI 6.4 to 8.3)
Docetaxel (Taxotere)ApprovedSmall moleculeMicrotubules (tubulin)not yet gradedNo reviewed efficacy summary in this indication
NivolumabApprovedMonoclonal antibodyPD-1Partial signal
NCT02105636: Overall Survival (OS) (From date of randomization to date of death (Up to approximately 18 months)): Nivolumab 3mg/kg 7.49 Months (95% CI 5.49 to 9.1) | Investigators Choice 5.06 Months (95% CI 4.04 to 6.05)
Opdivo QvantigApprovedMonoclonal antibodyPD-1not yet gradedNo reviewed efficacy summary in this indication
PembrolizumabApprovedMonoclonal antibodyPD-1Partial signal
NCT02358031: Primary endpoint, overall survival at a pre-specified interim analysis: pembrolizumab plus platinum/fluorouracil vs cetuximab plus platinum/fluorouracil, median 13.0 vs 10.7 months, HR 0.77; pembrolizumab alone vs cetuximab-chemotherapy in PD-L1 CPS >=1, HR 0.65 (95% CI 0.53 to 0.80) (KEYTRUDA label, KEYNOTE-048).
Rybrevant Faspro (amivantamab And Hyaluronidase-Lpuj)ApprovedMultispecific antibodyEGFR x c-METnot yet gradedNo reviewed efficacy summary in this indication
AmivantamabPhase 3Multispecific antibodyEGFR x c-METnot yet gradedNo reviewed efficacy summary in this indication
CPO301Phase 3Antibody–drug conjugateEGFRnot yet gradedNo reviewed efficacy summary in this indication
VolrustomigPhase 3Multispecific antibodyPD-1 x CTLA-4not yet gradedNo reviewed efficacy summary in this indication
OrdastobartPhase 2/3Monoclonal antibodyOX40 (agonist)not yet gradedNo reviewed efficacy summary in this indication
IzalontamabPhase 2Multispecific antibodyEGFR + HER3not yet gradedNo reviewed efficacy summary in this indication
Ozuriftamab VedotinPhase 2Antibody–drug conjugateROR2Partial signalNo reviewed efficacy summary in this indication
ALE.P02Phase 1/2Antibody–drug conjugateClaudin-1 (CLDN1)not yet gradedNo reviewed efficacy summary in this indication
PepinemabPhase 1/2Monoclonal antibodySEMA4Dnot yet gradedNo reviewed efficacy summary in this indication
BuparlisibDiscontinuedSmall moleculePI3K inhibitor (pan-class I)not yet gradedNo reviewed efficacy summary in this indication

Upcoming events

(9 total)

Estimated primary-completion dates from ClinicalTrials.gov. These are registry estimates, never confirmed readout dates; they can move as trials progress.

Follow NBTXR3 to get an email as a readout nears, when a date moves, or when a study changes status. Needs a free account.

Add these readouts to your calendar: Apple or Outlook · Google Calendar · .ics link. The calendar updates when a registry date moves.

2026 (1)
December 2026 (1)
Phase 1Borderline Resectable Pancreatic Adenocarcinoma, Locally Advanced Pancreatic Ductal Adenocarcinoma …Active not recruiting
Est. primary completion 2026-12-31 · NCT04484909 · CT.gov ↗
What to watch
2027 (2)
April 2027 (1)
Phase 1Non-Small Cell Lung CancerActive not recruiting
Est. primary completion 2027-04-30 · NCT03589339 · CT.gov ↗
What to watch
October 2027 (1)
Phase 1Cervical Esophagus Adenocarcinoma, Clinical Stage II Esophageal Adenocarcinoma AJCC v8 …Recruiting
Est. primary completion 2027-10-31 · NCT04615013 · CT.gov ↗
What to watch
2028 (6)
February 2028 (1)
Phase 1/2Advanced Malignant Solid Neoplasm, Metastatic Malignant Neoplasm in the Liver, Metastatic Malignant Neoplasm in the Lung …Recruiting
Est. primary completion 2028-02-01 · NCT05039632 · CT.gov ↗
What to watch
March 2028 (1)
Phase 1Non-Small Cell Lung CancerActive not recruiting
Est. primary completion 2028-03-31 · NCT04505267 · CT.gov ↗
What to watch
June 2028 (1)
Phase 3Carcinoma, Squamous CellRecruiting
Est. primary completion 2028-06-30 · NCT04892173 · CT.gov ↗
What to watch
July 2028 (1)
Phase 1Head and Neck Squamous Cell CarcinomaRecruiting
Est. primary completion 2028-07-14 · NCT07219212 · CT.gov ↗
What to watch
August 2028 (1)
Phase 1/2Non-Small Cell Lung CancerRecruiting
Est. primary completion 2028-08-30 · NCT07224152 · CT.gov ↗
What to watch
December 2028 (1)
Phase 2Non-Small Cell Lung CancerRecruiting
Est. primary completion 2028-12-31 · NCT06667908 · CT.gov ↗
What to watch

See the full readout calendar ↗